Literature DB >> 6779929

Reduced dopamine-beta-hydroxylase activity in Alzheimer's disease.

A J Cross, T J Crow, E K Perry, R H Perry, G Blessed, B E Tomlinson.   

Abstract

The activity of the noradrenergic marker enzyme dopamine-beta-hydroxylase was measured in brains removed postmortem from control patients and patients with Alzheimer's disease. Enzyme activity was decreased in the frontal and temporal cortices and hippocampus in patients with Alzheimer's disease, but was within the normal range in patients with depression, multiinfarct dementia, and terminal coma.The decrease in enzyme activity in Alzheimer's disease may reflect an abnormality of cortical noradrenergic fibres in some patients with the disease.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6779929      PMCID： PMC1503892          DOI： 10.1136/bmj.282.6258.93

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


  15 in total

1.  Regional distribution of enzymes associated with neurotransmission by monoamines, acetylcholine and GABA in the human brain.

Authors:  A V Mackay; P Davies; A J Dewar; C M Yates
Journal:  J Neurochem       Date:  1978-04       Impact factor: 5.372

2.  Selective vulnerability of neurones in organic dementia.

Authors:  J A Spillane; P White; W J Goodhardt; R H Flack; D M Bowen; A N Davison
Journal:  Nature       Date:  1977-04-07       Impact factor: 49.962

3.  Accelerated ageing or selective neuronal loss as an important cause of dementia?

Authors:  D M Bowen; P White; J A Spillane; M J Goodhardt; G Curzon; P Iwangoff; W Meier-Ruge; A N Davison
Journal:  Lancet       Date:  1979-01-06       Impact factor: 79.321

4.  Selective loss of central cholinergic neurons in Alzheimer's disease.

Authors:  P Davies; A J Maloney
Journal:  Lancet       Date:  1976-12-25       Impact factor: 79.321

5.  Some observations on the interaction of dopamine-beta-hydroxylase and its natural inhibitors in the rat brain.

Authors:  P H Yu; A A Boulton; P H Wu
Journal:  Can J Biochem       Date:  1976-11

6.  The activities of brain dopamine-beta-hydroxylase and catechol-O-methyl transferase in schizophrenics and controls.

Authors:  A J Cross; T J Crow; W S Killpack; A Longden; F Owen; G J Riley
Journal:  Psychopharmacology (Berl)       Date:  1978-10-31       Impact factor: 4.530

7.  [Catecholaminergic axons in the human cerebral cortex. Observation by histofluorescence of cerebral biopsies in 2 cases of Alzheimer's disease].

Authors:  B Berger; R Escourolle; M A Moyne
Journal:  Rev Neurol (Paris)       Date:  1976-03       Impact factor: 2.607

8.  Aluminum levels in brain in Alzheimer's disease.

Authors:  G A Trapp; G D Miner; R L Zimmerman; A R Mastri; L L Heston
Journal:  Biol Psychiatry       Date:  1978-12       Impact factor: 13.382

9.  Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue.

Authors:  E K Perry; P H Gibson; G Blessed; R H Perry; B E Tomlinson
Journal:  J Neurol Sci       Date:  1977-11       Impact factor: 3.181

10.  Memory impairment in Korsakoff's psychosis: a correlation with brain noradrenergic activity.

Authors:  W J McEntee; R G Mair
Journal:  Science       Date:  1978-11-24       Impact factor: 47.728
View more
  32 in total

1.  Metabolomic changes in autopsy-confirmed Alzheimer's disease.

Authors:  Rima Kaddurah-Daouk; Steve Rozen; Wayne Matson; Xianlin Han; Christine M Hulette; James R Burke; P Murali Doraiswamy; Kathleen A Welsh-Bohmer
Journal:  Alzheimers Dement       Date:  2010-11-13       Impact factor: 21.566

2.  Polymorphisms in the aldehyde dehydrogenase 2 and dopamine β hydroxylase genes are not associated with Alzheimer's disease.

Authors:  Miwa Komatsu; Nobuto Shibata; Tohru Ohnuma; Bolati Kuerban; Katrin Tomson; Aiko Toda; Yuko Tagata; Tomoko Nakada; Hiromi Shimazaki; Heii Arai
Journal:  J Neural Transm (Vienna)       Date:  2013-11-08       Impact factor: 3.575

3.  Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group.

Authors:  F P Zemlan
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 4.  Neurochemical aspects of Alzheimer's disease: involvement of membrane phospholipids.

Authors:  A A Farooqui; L Liss; L A Horrocks
Journal:  Metab Brain Dis       Date:  1988-03       Impact factor: 3.584

5.  Genotype-independent decrease in plasma dopamine beta-hydroxylase activity in Alzheimer's disease.

Authors:  Maja Mustapic; Paola Presecki; Nela Pivac; Ninoslav Mimica; Patrick R Hof; Goran Simic; Vera Folnegovic-Smalc; Dorotea Muck-Seler
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-02-13       Impact factor: 5.067

6.  A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease.

Authors:  A Little; R Levy; P Chuaqui-Kidd; D Hand
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-08       Impact factor: 10.154

7.  Long survival in Fukuyama congenital muscular dystrophy: occurrence of neurofibrillary tangles in the nucleus basalis of Meynert and locus ceruleus.

Authors:  K Takada; Y S Rin; S Kasagi; K Sato; H Nakamura; J Tanaka
Journal:  Acta Neuropathol       Date:  1986       Impact factor: 17.088

8.  A comparison of changes in the nucleus basalis and locus caeruleus in Alzheimer's disease.

Authors:  D M Mann; P O Yates; B Marcyniuk
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-02       Impact factor: 10.154

9.  The noradrenergic system in Alzheimer and multi-infarct dementias.

Authors:  D M Mann; P O Yates; J Hawkes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-02       Impact factor: 10.154

10.  HP 749 enhances calcium-independent release of [3H]norepinephrine from rat cortical slices and synaptosomes.

Authors:  C P Smith; F P Huger; W Petko; S Kongsamut
Journal:  Neurochem Res       Date:  1994-10       Impact factor: 3.996
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.